PT-141 bremelanotide — 7 critical facts about the evidence.

PT-141 bremelanotide is unique in the research peptide landscape for one reason that separates it from almost every other compound in this space: it has FDA approval. Most peptides discussed in research communities have no approved indication anywhere. PT-141 bremelanotide — sold as Vyleesi — was FDA-approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, backed by Phase 3 RCT data from over 1,200 participants. That regulatory milestone doesn’t make it appropriate for every use case, but it does mean its evidence base is substantially more robust than most research peptides.

This guide covers the complete PT-141 bremelanotide picture: what it is, how its mechanism differs fundamentally from conventional sexual health treatments, what the Phase 3 trials showed, the male evidence, side effects, UK legal status, and how it fits into the broader peptide landscape. Sexual health clinical guidance is available through the British Association for Sexual Health and HIV.

PT-141 Bremelanotide — fact 1: what it is and where it came from

The compound is a synthetic cyclic heptapeptide derived from Melanotan II — itself developed from alpha-melanocyte-stimulating hormone (α-MSH) at the University of Arizona in the 1980s. The original goal of the research program was entirely different: develop a “universal tan” peptide that could stimulate melanogenesis (skin darkening) without UV exposure. Melanotan II achieved this through melanocortin receptor agonism, but during early clinical trials researchers observed an unexpected and significant secondary effect in male subjects: spontaneous sexual arousal.

This serendipitous discovery redirected the development program. Palatin Technologies synthesised bremelanotide as a more selective derivative of Melanotan II — retaining the sexual arousal mechanism while reducing the non-selective side effects (nausea, excessive skin darkening, elevated blood pressure) of its parent compound. After years of clinical development, the compound received FDA approval in June 2019 under the brand name Vyleesi — becoming the first non-hormonal, centrally-acting treatment for female sexual desire disorder to gain regulatory approval.

PT-141 Bremelanotide — fact 2: the central mechanism

The most important distinction is mechanistic. Where PDE5 inhibitors like sildenafil (Viagra) act peripherally — improving blood flow to genital tissue — PT-141 bremelanotide acts centrally on the brain itself. Specifically, it targets melanocortin receptors MC3R and MC4R in the hypothalamus, activating dopamine-linked pathways that generate the neurological experience of sexual desire.

This central mechanism is why PT-141 bremelanotide addresses low desire rather than physical performance mechanics. The distinction matters enormously in practice: a person who has no difficulty with arousal or performance but experiences a fundamental absence of desire — the defining symptom of HSDD — is not helped by improving peripheral blood flow. PT-141 bremelanotide addresses the neurological underpinning of desire itself, which is why its approved indication is specifically hypoactive sexual desire disorder rather than erectile dysfunction or arousal disorder.

The mechanism also explains why bremelanotide is dose-timed differently from PDE5 inhibitors. The FDA-approved Vyleesi protocol is 1.75mg subcutaneous injection 45 minutes before sexual activity — allowing time for central dopamine pathway engagement to develop.

PT-141 Bremelanotide — fact 3: Phase 3 evidence — the RECONNECT trials

The evidence base is anchored by the RECONNECT programme — two identical Phase 3, randomised, double-blind, placebo-controlled, multicentre trials enrolling a combined 1,267 premenopausal women with confirmed HSDD. These trials form the basis of the FDA approval and represent the most rigorous human evidence for any peptide in the research community.

RECONNECT-1 (n=634) and RECONNECT-2 (n=636) both used 1.75mg bremelanotide subcutaneous injection as-needed over 24 weeks. Primary endpoints measured improvement in desire (FSFI-D score) and reduction in HSDD-related distress (FSDS-DAO score). Results across both trials:

• Approximately 25% of women on bremelanotide reported meaningful improvement in desire versus 17% on placebo
• Statistically significant improvement in both desire and distress scores versus placebo
• Improvement observed as early as 4 weeks
• Effects maintained over the 24-week treatment period

The honest characterisation of the RECONNECT data is that effect sizes are modest but real. An absolute improvement of approximately 8 percentage points over placebo is not transformative — but it is meaningful for a condition that previously had almost no pharmacological options, and the effect is supported by two independent Phase 3 trials rather than a single study.

PT-141 Bremelanotide — fact 4: evidence in men

The FDA approval covers only premenopausal women with HSDD — but use in men has a separate evidence stream that has grown substantially since 2020. The original discovery of bremelanotide’s sexual arousal properties came from male subjects, and Phase I/II trials in men with erectile dysfunction were conducted in the early 2000s.

Phase I/II trials (Molinoff et al. 2003-2006) showed positive effects in men with ED, including those who hadn’t responded adequately to PDE5 inhibitors. A 2024 observational study by Goldstein and Goldstein found subjective improvements in 21 men with various sexual dysfunctions using subcutaneous bremelanotide as-needed — providing more contemporary data for the male use case.

Critically, as of 2026, no company has filed for FDA approval of bremelanotide for any male indication. A Palatin Technologies Phase 2b trial combining bremelanotide with a PDE5 inhibitor for PDE5i-nonresponsive men has results pending as of April 2026. If positive, this would be the first Phase 3-ready dataset for male indications. Until then, male use remains off-label with smaller-scale but consistent evidence.

PT-141 Bremelanotide — fact 5: side effects

The most common side effect is nausea — reported in 40% of the treated group in the RECONNECT trials. This is significantly higher than most peptide side effect rates and is the primary tolerability challenge for PT-141 bremelanotide in practice. The nausea typically peaks 30-60 minutes after injection and resolves within 3 hours in most cases.

Practical mitigation strategies for nausea include:

• Eating a light, low-fat meal before injection (high-fat meals worsen nausea)
• Using abdominal rather than thigh injection sites
• Starting at 1mg rather than the full 1.75mg for the first 1-2 doses
• Discussing prophylactic antiemetics (such as ondansetron) with a prescribing clinician

Other side effects include transient blood pressure elevation (observed in trials, typically resolving within 12 hours), flushing, and injection site reactions. Temporary skin hyperpigmentation is possible with repeated use, reflecting melanocortin pathway activation. The FDA limits the Vyleesi protocol to a maximum of 8 doses per month.

PT-141 Bremelanotide — fact 6: legal status UK vs FDA

The regulatory status differs significantly between the US and UK. In the US, Vyleesi is an FDA-approved prescription medicine for premenopausal women with HSDD — legally prescribable, dispensed by licensed pharmacies, manufactured under FDA quality oversight.

In the UK, bremelanotide has no MHRA marketing authorisation. The FDA approval does not automatically extend to UK regulatory status. It cannot be legally prescribed by UK doctors or dispensed by UK pharmacies as a medicine. It can be purchased as a research compound for laboratory use — but compounded bremelanotide lacks the FDA batch-level quality and sterility oversight of the approved Vyleesi formulation.

Bremelanotide is not a controlled substance under the UK Misuse of Drugs Act 1971. It is also not currently on the WADA prohibited list — making it one of the few peptides without both a controlled substance classification and a WADA prohibition.

PT-141 Bremelanotide — fact 7: where it fits in the peptide landscape

Bremelanotide occupies a unique position in the research peptide space: it is the only compound in the category to have Phase 3 RCT data from 1,267 participants supporting an FDA-approved indication. That regulatory milestone puts bremelanotide in a different evidence tier from compounds like BPC-157 (no human RCTs) or even GH peptide stacks (no combined RCTs).

Its specific application — addressing the neurological underpinning of sexual desire — makes it relevant to a large and underserved population. HSDD affects an estimated 10% of premenopausal women in the UK, yet had almost no pharmacological treatment options before PT-141 bremelanotide’s development. For men with desire-based rather than mechanics-based sexual dysfunction, the Phase I/II evidence and growing clinical experience provide reasonable grounds for off-label research interest.

What bremelanotide does not do is produce weight loss, body recomposition, or metabolic health improvements — which distinguishes it from the compounds most relevant to weight management research. For anyone whose primary interest in peptides is metabolic rather than sexual health, PT-141 bremelanotide is an interesting and well-evidenced compound in a completely separate functional category.

For compounds targeting metabolic goals and weight loss, read our best peptides for fat loss UK guide. For the highest-evidence weight management research compound, explore our Synedica Retatrutide product page.